Compare First Trust Cloud Computing ETF (SKYY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust Cloud Computing ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? First Trust Cloud Computing ETF trades at $174.78 (market cap $3.47B), while Vertex Pharmaceuticals Incorporated trades at $511.71 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 36.8× First Trust Cloud Computing ETF's market cap, and First Trust Cloud Computing ETF is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust Cloud Computing ETF for 85 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SKYY | VRTX | |
|---|---|---|
Market Cap | $3.47B | $127.55B |
Volume | 176,159 | 1,487,944 |
52-Week High | $171.01 | $557.96 |
52-Week Low | $104.16 | $407.37 |
Typical Hold Time | 85 Days | 120 Days |
Sector | — | Health |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Trust Cloud Computing ETF (SKYY) trades at $174.09, up 1.94% with bullish technical signals from moving averages. The ETF recently hit a new 52-week high, reflecting strong momentum in cloud computing stocks driven by AI infrastructure demand. Technical indicators show support at $169 and resistance at $171-173, with the current price near recent highs.
SKYY offers diversified exposure to cloud infrastructure and software companies benefiting from secular trends in AI adoption and digital transformation. Key risks include sector concentration and market volatility, while institutional sentiment remains positive given the long-term growth prospects in cloud computing.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
